Clinical and experimental study on treatment of acute respiratory tract infection with Shuanghuanglian Aerosol

Yue-Hong Wang; Kai-Jian Xu; Wei-Shi Jiang; Fu-Zhen Lu; Meng-Ying Hu; Zeng-Ke Zhe; Feng Gao; Jing-Wei Zhang; Xiao-Lian He; Feng-Yang Hong

doi:10.1007/BF02934238

Your Location：

Home >

Browse articles >

Clinical and experimental study on treatment of acute respiratory tract infection with Shuanghuanglian Aerosol

Updated：2021-08-27

- Clinical and experimental study on treatment of acute respiratory tract infection with Shuanghuanglian Aerosol
- Chinese Journal of Integrative Medicine Vol. 2, Issue 3, Pages: 162-165(1996)
- Affiliations：
  
  1. Second Affiliated Hospital of Harbin Medical University,Harbin
  2. Harbin Municipal Children’s Hospital,Harbin
  3. First Affiliated Hospital of Harbin Medical University,Harbin
- Author bio：
- Funds：
- DOI：10.1007/BF02934238
  CLC：
- Published：1996，
Scan for full text
Wang, YH., Xu, KJ., Jiang, WS. et al. Clinical and experimental study on treatment of acute respiratory tract infection with Shuanghuanglian Aerosol., CJIM 2, 162–165 (1996). https://doi.org/10.1007/BF02934238

Yue-Hong Wang, Kai-Jian Xu, Wei-Shi Jiang, et al. Clinical and experimental study on treatment of acute respiratory tract infection with Shuanghuanglian Aerosol. [J]. Chinese Journal of Integrative Medicine 2(3):162-165(1996)
Wang, YH., Xu, KJ., Jiang, WS. et al. Clinical and experimental study on treatment of acute respiratory tract infection with Shuanghuanglian Aerosol., CJIM 2, 162–165 (1996). https://doi.org/10.1007/BF02934238 DOI：

Yue-Hong Wang, Kai-Jian Xu, Wei-Shi Jiang, et al. Clinical and experimental study on treatment of acute respiratory tract infection with Shuanghuanglian Aerosol. [J]. Chinese Journal of Integrative Medicine 2(3):162-165(1996) DOI： 10.1007/BF02934238.

摘要

Two hundred and two cases of acute respiratory tract infection (ARI) were treated with Shuanghuanglian (SHL) aerosol. In these cases

the majority were virus infection and 64% of them was caused by the respiratory syncytial virus (RSV). The virostatic and bacteriostatic test were done in vitro by the cell culture method and it was shown that SHL could inhibit the RSV

para-influenza virus I ~ IV and 23 kinds of pathogenic bacteria such as Staphylococcus aureus etc. The bacteriostatic effect was positively correlated to the SHL concentration. Experimental study showed that SHL could enhance the NK cell activity

promote the production of α-interferon and raise the rate of lymphocyte transformation. The controlled observation on SHL preparation with various dosage-forms revealed that the SHL aerosol in treating early ARI showed better results than that of injections and oral liquid symptomatologically (P<0.05). The total effective rate was 96%.

Abstract

Two hundred and two cases of acute respiratory tract infection (ARI) were treated with Shuanghuanglian (SHL) aerosol. In these cases

关键词

Shuanghuanglian aerosolacute respiratory infectionvirus inhibitionantibiogram

Keywords

Shuanghuanglian aerosolacute respiratory infectionvirus inhibitionantibiogram

references

4 1985:6, 31, 71.

1984:5, 21.

1992; 107.

1988:10(22):34.

1990;68.

Xu KJ, Su. KX, Lu YC. Human biavailability of the injection and the aerosol of Shuanghuanglian CA 1993, 118(20): 417.

Xu. KJ, Zhuang H, Wu LH. Stability of Shuanghuanglian aerosol MK 1993; 33(2):2366.

1988;10(2):31.

FULL TEXT LINK

More>

Views

712

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Prominent personnel

Related Author

No data

Related Institution

—Outstanding Pediatrician of Integrated Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰